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Figure S1. PSA and PUR-4 data in biopsy patients categorized on D’Amico and PSA in the nine RPx men. For ‘a’ and ‘b’ 
Data were analyzed using a non-parametric Kruskal-Wallis analysis of variance followed by Games-Howell post-hoc anal-
ysis. A) PUR-4 in men categorized as No Evidence of prostate Cancer (NEC) and D’Amico risk groups low, intermediate 
and high-risk. PUR-4 correlated with increasing D’Amico risk group (Pearson’s correlation r=0.62, p=3.2e-30). ’*’ indicates 
a significant difference (p<0.05). B) PSA correlated with increasing D’Amico risk group (Pearson’s correlation r=0.73, 
p=9.8e-47). C) PUR-4 and PSA for the nine prostatectomy cases, no correlation was found (rho = -0.33, p=0.39).
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Table S1. Clinical characteristics and PUR scores for biopsy cases categorized by Gleason Grade and subcategorized by % biopsy cores positive. All data presented as: ‘Median (IQR)’, 
Abbreviations: IQR, interquartile range; GG, Gleason Grade; NEC, No Evidence of Cancer; US, Ultrasound; Age and PSA at time of urine collection; PSA, prostate specific antigen; 
PSAD, PSA density (PSA/US prostate volume). PUR-1-4, Prostate urine risk signatures 1-4, NA, Not applicable. 
 NEC GG1 GG2 GG3 GG4 GG5 GG1(S)  GG1(L)    GG2(S)  GG2(L)    GG3(S)  GG3(L)    
Total (%) 62 (22.4%)  93 (33.6%)  61 (22.0%)  38 (13.7%) 12 (4.3%) 11 (4.0%) 46 (16.6%) 47 (17%) 30 (10.8%) 31 (11.2%) 19 (6.9%) 19 (6.9%) 
Age in years,   66 (17) 67 (6.5) 68 (9) 73 (8.25) 71 (12.25) 69 (8.5) 67 (8) 69.5 (8.25) 67.5 (9.5) 69 (7) 75 (7) 70 (10) 
PSA ng/ml 1.2 (2) 7.3 (5.5) 7.8 (4.5) 11.35 (11.03) 13.45 (12.68) 18.7 (45.95) 6.75 (5.05) 7.5 (6.2) 6.2 (2.15) 9.5 (5.25) 11.2 (6.75) 11.6 (15.9) 
Prostate volume 
US 
NA 23 (7.5) 42.43 (24.73) 49.03 (28.42) 50.39 (22.89) 55.93 (24.97) 25.08 (32.45) 22 (5.25) 55.29 (33.62) 37.95 (20.96) 59 (43.28) 35.94 (18.03) 
PSAD NA 0.292 (0.315) 0.179 (0.122) 0.256 (0.227) 0.287 (0.385) 0.31 (0.565) 0.248 (0.272) 0.417 (0.392) 0.123 (0.055) 0.24 (0.309) 0.19 (0.098) 0.323 (0.454) 
biopsy Cores 
taken 
NA 11 (4) 9 (2) 8 (6) 5.5 (5.25) 4 (6.5) 12 (2) 9 (4) 10 (2.75) 8 (2) 10 (3) 6 (4) 
Biopsy Cores 
positive 
NA 1 (1) 3 (3) 3.5 (2.75) 3.5 (3.5) 4 (5) 1 (0) 2 (1.5) 2 (2) 5 (2.5) 2 (2) 4 (2.5) 
% biopsy cores 
positive 
NA 12.5 (16.67) 37.5 (42.5) 50 (58.57) 50 (36.39) 100 (0) 8.333 (4.17) 18.182 (16.67) 20 (14.21) 62.5 (25) 28.571 (31.79) 80 (35.42) 
% biopsy cores 
positive/US 
NA 0.003 (0.004) 0.001 (0.001) 0.001 (0.001) 0.001 (0.001) 0.001 (0.002) 0.003 (0.004) 0.003 (0.004) 0.001 (0) 0.001 (0.001) 0.001 (0) 0.001 (0.002) 
PUR-1 0.358 (0.206) 0.119 (0.165) 0.078 (0.145) 0.03 (0.119) 0.059 (0.04) 0.07 (0.059) 0.112 (0.104) 0.129 (0.202) 0.152 (0.135) 0.041 (0.061) 0.042 (0.126) 0.019 (0.094) 
PUR-2 0.321 (0.036) 0.302 (0.078) 0.275 (0.151) 0.187 (0.217) 0.248 (0.07) 0.201 (0.124) 0.302 (0.06) 0.306 (0.099) 0.315 (0.059) 0.214 (0.143) 0.217 (0.178) 0.152 (0.197) 
PUR-3 0.256 (0.129) 0.442 (0.15) 0.452 (0.116) 0.475 (0.119) 0.506 (0.032) 0.489 (0.073) 0.45 (0.102) 0.417 (0.166) 0.411 (0.127) 0.491 (0.098) 0.473 (0.123) 0.483 (0.091) 




Table S2. Combined RPx and Biopsy clinical characteristics for the 9 radical prostatectomy (RPx) cases examined. GG = Gleason Grade group; Majority, data for most common GG 
found in each prostate; Highest GG, the highest GG found in each prostate; GP3, GP4, GP5, Gleason Pattern 3, 4, 5 respectively; Age, age at recruitment; US vol, Ultrasound volume of 
prostate; PCa, prostate cancer; All areas measured from scans of H&E slides (see methods); for GP3 and GP4 amount calculation see results; GG2+5 indicates GG2 cancer with a tertiary 
GP5 (<5% of all PCa); PUR-1-4, Prostate urine risk signatures 1-4. 


























PUR-1 PUR-2 PUR-3 PUR-4 
RPx 1 GG1 GG1, (+GP4<2%) GG1, (+GP4<2%) 5269.9 486.4 481.6 4.8 54 5.5 GG1 54.5 10 3 30.0 0.45 0.31 0.20 0.04 
RPx 2 GG2 GG2, <10% GP4 GG2, <10% GP4 3339.0 341.2 324.1 17.1 64 15 GG1 45.8 8 4 50.0 0.15 0.33 0.42 0.11 
RPx 3 GG2 GG2, <10% GP4 GG2, <10% GP4 4347.6 531.8 505.2 26.6 52 5.8 GG1 68.0 12 2 16.7 0.10 0.30 0.46 0.14 
RPx 4 GG2+5 GG2, <10% GP4 GG5, GP4+5 ≥50% 
GP4 
4606.0 254.5 233.9 20.5 70 8.4 GG3 59.0 10 3 30.0 0.01 0.08 0.48 0.44 
RPx 5 GG2 GG2, 10-25% GP4 GG2, 10-25% GP4 3643.2 172.1 143.3 28.8 66 5.2 GG2 35.2 9 2 22.2 0.17 0.34 0.39 0.10 
RPx 6 GG2 GG2, <10% GP4 GG2, 25-50% GP4 4529.7 364.0 302.0 62.0 68 6.7 GG2 36.1 28 18 66.7 0.00 0.03 0.35 0.62 
RPx 7 GG3 GG2, 25-50% GP4 GG3, 50-75% GP4 11991.1 92.9 54.8 38.0 67 10.3 GG2 85.6 9 1 11.1 0.23 0.35 0.35 0.08 
RPx 8 GG3 GG3, 50-75% GP4 GG3, 50-75% GP4 3729.6 158.7 60.3 98.4 65 7.4 GG2 46.0 23 3 13.0 0.01 0.08 0.47 0.44 
RPx 9 GG3 GG3, 75-90% GP4 GG3, 75-90% GP4 3851.4 664.4 122.2 542.2 75 2.9 GG3+5 38.0 10 8 80.0 0.00 0.04 0.40 0.56 
